Evidence map›Paper›PMID 41542563›Full record

ArticlebioRxiv : the preprint server for biology2026

NetMHCIIphosPan: a machine learning tool for predicting HLA class II antigen presentation of phosphorylated peptides.

Heli M Garcia Alvarez, Saghar Kaabinejadian, Hooman Yari, Chloe M Shepherd, William H Hildebrand, Alessandro Sette, Bjoern Peters, Robert Parker, Nicola Ternette, Morten Nielsen

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Heli M Garcia AlvarezInstituto de Investigaciones Biotecnológicas (IIBIO), Consejo Nacional de Investigaciones Científicas y Técnicas, B1650HMQ, San Martín, Buenos Aires, Argentina.ORCID 0000-0002-4353-2942
Saghar KaabinejadianDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.ORCID 0000-0002-8434-8703
Hooman YariDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.ORCID 0000-0002-8285-7985
Chloe M ShepherdUniversity of Dundee, Dundee, DD15EH, Scotland, UK.ORCID 0000-0002-0149-7448
William H HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Alessandro SetteCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0001-7013-2250
Bjoern PetersCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-8457-6693
Robert ParkerUniversity of Oxford, Nuffield Department of Medicine, OX37DQ, UK.
Nicola TernetteUniversity of Dundee, Dundee, DD15EH, Scotland, UK.ORCID 0000-0002-9283-0743
Morten NielsenDepartment of Health Technology, Technical University of Denmark, DK-2800 Lyngby, Denmark.ORCID 0000-0001-7885-4311

Funding

IMMUNE EPITOPE AND ANALYSIS PROGRAM: Transplantation of organs, tissues and cells 75N93019C00001 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI WILSON, STEPHEN · 2019 to 2025
$23.1M
THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCEU24CA248138 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN, SETTE, ALESSANDRO · 2021 to 2025
$4.6M
NCI NIH HHS U24 CA248138NIAID NIH HHS 75N93019C00001
6 · The paper itself

Abstract

Phosphorylated peptides presented by human leukocyte antigen (HLA) class II molecules play pivotal roles in immune regulation, yet their characterization and prediction remain challenging due to data noise and limited HLA coverage. Here, we introduce NetMHCIIphosPan, a prediction method for HLA-II antigen presentation of phosphorylated peptides, developed using mass spectrometry (MS)-based immunopeptidomics datasets. Employing a refined peptide identification workflow, we reanalyzed earlier HLA-II phospholigand datasets and trained predictive models, achieving superior performance compared to models trained on original data. Binding motif analysis revealed that HLA-specific preferences for phospholigands closely aligned with those of unmodified ligands. Incorporating unmodified ligands into training further enhanced predictive accuracy, particularly for HLA-DP and HLA-DQ molecules. NetMHCIIphosPan outperformed existing tools, such as NetMHCIIpan-4.3 and MixMHC2pred-1.3, for prediction of HLA antigen presentation of phosphorylated peptides demonstrating robustness and utility. This work establishes NetMHCIIphosPan as a state-of-the-art tool for understanding the HLA-II phospholigandome, with potential applications in immunotherapy and vaccine design.

Indexed as

antigen presentationHLA class IIimmunoinformaticsimmunopeptidomicsmachine learningneural networksphosphorylationpost-translational modificationpredictive methods

Identifiers

PMID41542563
PMCPMC12803180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.